» Articles » PMID: 35222350

Precision Vaccine Development: Cues From Natural Immunity

Overview
Journal Front Immunol
Date 2022 Feb 28
PMID 35222350
Authors
Affiliations
Soon will be listed here.
Abstract

Traditional vaccine development against infectious diseases has been guided by the overarching aim to generate efficacious vaccines normally indicated by an antibody and/or cellular response that correlates with protection. However, this approach has been shown to be only a partially effective measure, since vaccine- and pathogen-specific immunity may not perfectly overlap. Thus, some vaccine development strategies, normally focused on targeted generation of both antigen specific antibody and T cell responses, resulting in a long-lived heterogenous and stable pool of memory lymphocytes, may benefit from better mimicking the immune response of a natural infection. However, challenges to achieving this goal remain unattended, due to gaps in our understanding of human immunity and full elucidation of infectious pathogenesis. In this review, we describe recent advances in the development of effective vaccines, focusing on how understanding the differences in the immunizing and non-immunizing immune responses to natural infections and corresponding shifts in immune ontogeny are crucial to inform the next generation of infectious disease vaccines.

Citing Articles

A vaccine platform targeting lung-resident memory CD4 T-cells provides protection against heterosubtypic influenza infections in mice and ferrets.

Ko K, Bae H, Park J, Lee J, Park S, Heo J Nat Commun. 2024; 15(1):10368.

PMID: 39609429 PMC: 11604757. DOI: 10.1038/s41467-024-54620-4.


The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 support and .

Brook B, Checkervarty A, Barman S, Sweitzer C, Bosco A, Sherman A iScience. 2024; 27(11):111055.

PMID: 39569372 PMC: 11576392. DOI: 10.1016/j.isci.2024.111055.


Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption.

Kumar K, Honda-Okubo Y, Sakala I, Singh K, Petrovsky N, Salunke D ACS Med Chem Lett. 2024; 15(10):1677-1684.

PMID: 39411538 PMC: 11472459. DOI: 10.1021/acsmedchemlett.4c00200.


The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Komlodi-Pasztor E, Escarra-Senmarti M, Bazer D, Bhatnagar A, Perez Heydrich C, Messmer M Front Immunol. 2024; 15:1433442.

PMID: 39295862 PMC: 11408186. DOI: 10.3389/fimmu.2024.1433442.


Precision Nanovaccines for Potent Vaccination.

Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z JACS Au. 2024; 4(8):2792-2810.

PMID: 39211600 PMC: 11350730. DOI: 10.1021/jacsau.4c00568.


References
1.
Hatherill M, White R, Hawn T . Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Front Microbiol. 2020; 10:3154. PMC: 7002896. DOI: 10.3389/fmicb.2019.03154. View

2.
Angelidou A, Levy O . Vaccination of Term and Preterm Infants. Neoreviews. 2020; 21(12):e817-e827. DOI: 10.1542/neo.21-12-e817. View

3.
Nicoli F, Appay V . Immunological considerations regarding parental concerns on pediatric immunizations. Vaccine. 2017; 35(23):3012-3019. DOI: 10.1016/j.vaccine.2017.04.030. View

4.
Isakova-Sivak I, Rudenko L . Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015; 14(10):1313-29. DOI: 10.1586/14760584.2015.1075883. View

5.
Kirman J, Henao-Tamayo M, Agger E . The Memory Immune Response to Tuberculosis. Microbiol Spectr. 2017; 4(6). DOI: 10.1128/microbiolspec.TBTB2-0009-2016. View